EFM
CRVS icon

E Fund Management’s Corvus Pharmaceuticals CRVS Stock Holding History

E Fund Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$172K Sell
11,491
-2,665
-19% -$37K ﹤0.01% 460
2026
Q1 		$207K Buy
+14,156
New +$226K 0.01% 447

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

E Fund Management's CRVS Position: Q2 2026 in Review

E Fund Management reduced its Corvus Pharmaceuticals (CRVS) stake by 19% in Q2 2026, selling an estimated $37K and leaving 11,491 shares worth $172K. The position accounts for ﹤0.01% of the portfolio, ranked #460.

E Fund Management first reported a position in CRVS in Q1 2026 and has held it in 2 quarters since. The position peaked at $207K in Q1 2026. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • E Fund Management held 11,491 shares of Corvus Pharmaceuticals worth $172K as of Q2 2026.
  • E Fund Management sold 2,665 Corvus Pharmaceuticals shares in Q2 2026, an estimated $37K.
  • Corvus Pharmaceuticals made up ﹤0.01% of E Fund Management's portfolio in Q2 2026, its #460 holding.
  • E Fund Management first reported a position in Corvus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • E Fund Management's Corvus Pharmaceuticals position peaked at $207K in Q1 2026.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.